LON:ONCOncimmune Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Oncimmune Holdings PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 125 -2.50 (-1.96 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range 123.01Now: GBX 125▼ 126.8550-Day Range 96.50MA: GBX 123.95▼ 13852-Week Range 30Now: GBX 125▼ 139.95Volume4,828 shsAverage Volume33,554 shsMarket Capitalization£79.38 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Oncimmune Holdings Plc, an early cancer detection company, develops and commercializes products to diagnose cancer in the United Kingdom and North America. The company engages in the development of autoantibody based platform to allow cancer detection to a range of solid cancer tumor types. It offers EarlyCDT-Lung, a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. The company also develops EarlyCDT-Liver to aid in the detection and confirmation of hepatocellular carcinoma (HCC) in high-risk patients with liver lesions of all sizes tests for liver cancer. Oncimmune Holdings Plc was incorporated in 2015 and is headquartered in Nottingham, the United Kingdom.Read More Beat the Market (BTM) Rank™ 1.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 150, Oncimmune has a potential upside of 20.0% from its current price of GBX 125.Amount of Analyst CoverageOncimmune has only been the subject of 1 research reports in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesOncimmune has received 68 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOncimmune has received 94 “underperform” votes. (Add your “underperform” vote.)Community SentimentOncimmune has received 58.02% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Oncimmune and other stocks. Vote “Outperform” if you believe ONC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOncimmune does not currently pay a dividend.Dividend GrowthOncimmune does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncimmune insiders have bought more of their company's stock than they have sold. Specifically, they have bought £40,739.60 in company stock and sold GBX 0 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncimmune is -7.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncimmune is -7.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncimmune has a P/B Ratio of 34.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.22 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolLON:ONC Previous Symbol CUSIPN/A CIKN/A Weboncimmune.com Phone+44-115-8231869Debt Debt-to-Equity Ratio375.32 Current Ratio3.91 Quick Ratio3.84Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£358,000.00 Price / Sales221.72 Cash FlowGBX 11.40 per share Price / Cash Flow10.97 Book ValueGBX 3.60 per share Price / Book34.72Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees52 Outstanding Shares63,500,000Market Cap£79.38 million Next Earnings DateN/A OptionableNot Optionable LSE:ONC Rates by TradingView Receive ONC News and Ratings via Email Sign-up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Oncimmune (LON:ONC) Frequently Asked Questions How has Oncimmune's stock been impacted by COVID-19 (Coronavirus)? Oncimmune's stock was trading at GBX 70.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ONC stock has increased by 77.3% and is now trading at GBX 125. View which stocks have been most impacted by Coronavirus. How were Oncimmune's earnings last quarter? Oncimmune Holdings PLC (LON:ONC) released its quarterly earnings results on Tuesday, February, 13th. The company reported ($5.70) earnings per share (EPS) for the quarter. The firm earned $0.08 million during the quarter. View Oncimmune's earnings history. What price target have analysts set for ONC? 0 brokers have issued 12-month target prices for Oncimmune's shares. Their forecasts range from GBX 150 to GBX 150. On average, they anticipate Oncimmune's stock price to reach GBX 150 in the next twelve months. This suggests a possible upside of 20.0% from the stock's current price. View analysts' price targets for Oncimmune. Has Oncimmune been receiving favorable news coverage? Press coverage about ONC stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oncimmune earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Oncimmune. Who are some of Oncimmune's key competitors? Some companies that are related to Oncimmune include Renalytix Ai (RENX), Volpara Health Tech (VHT), Akumin (AKU), MaxCyte (MXCT), Exagen (XGN), Yourgene Health (YGEN), Senseonics (SENS), Palatin Technologies (PTN), Lexagene (LXG), Oncosil Medical (OSL), SQI Diagnostics (SQD), Genedrive (GDR), BARD1 Life Sciences (BD1), Sernova (SVA) and GeneNews (GEN). View all competitors. What other stocks do shareholders of Oncimmune own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncimmune investors own include Actinium Pharmaceuticals (ATNM), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), Aphria (APHA), AquaBounty Technologies (AQB), Axsome Therapeutics (AXSM), BG Staffing (BGSF), Chimerix (CMRX) and Constellation Pharmaceuticals (CNST). Who are Oncimmune's key executives? Oncimmune's management team includes the following people: Dr. Adam Mark Hill Ph.D., CEO & Director (Age 39)Mr. Andrew Millet BA, FCA, MBA, Exec. (Age 52)Mr. Matthew Hall, Group Chief Financial OfficerDr. Laura J. Peek, Principal Scientist & Assistant Lab DirectorMr. Andrew Stewart, Gen. Counsel & Company Sec. What is Oncimmune's stock symbol? Oncimmune trades on the London Stock Exchange (LON) under the ticker symbol "ONC." How do I buy shares of Oncimmune? Shares of ONC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Oncimmune's stock price today? One share of ONC stock can currently be purchased for approximately GBX 125. How big of a company is Oncimmune? Oncimmune has a market capitalization of £79.38 million and generates £358,000.00 in revenue each year. Oncimmune employs 52 workers across the globe. What is Oncimmune's official website? The official website for Oncimmune is oncimmune.com. How can I contact Oncimmune? Oncimmune's mailing address is Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The company can be reached via phone at +44-115-8231869. This page was last updated on 7/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
